他是醫療行業私募基金BioRevolution的創始人，並于2007年至2013年在環球咨詢服務集團有限責任公司（Global Advisory Services Group, LLC）（總部位于紐約）擔任生物科技領域投資的顧問，專注于與國際醫藥公司發展潛在的戰略合作關系。阿吉萊拉先生于2002年6月至2007年1月在遠東證券（Great Eastern Securities, Inc.）和Sandgrain證券（Sandgrain Securities, Inc.）擔任高級理財顧問。從1999年4月直至加入Sandgrain之前，阿吉萊拉先生擔任Josephthal公司的高級副總裁，該公司後被後來被Fahnestock公司收購。阿吉萊拉先生自1984年任職于DH Blair 公司直至其被巴瑞頓資金集團（Barington Capital Group, L.P.）收購，並在後者任職至1999年4月。上述阿吉萊拉先生所任的每一個職位均與生物科技領域相關。這些職場經曆使得阿吉萊拉先生成爲投資生物科技公司（市值5億美元以下的生物科技公司）的專家。憑借在該領域的豐富經驗，阿吉萊拉先生自1998年12月起在致力于癌症研究的Vion制藥公司擔任了爲期12個月的融資顧問。
Dr. Lan Bo Chen
Dr. Chen is Professor Emeritus of Pathology at Harvard Medical School. He is the author of over 200 academic publications and is the founder of several successful biotechnology companies and ventures, including Fuji ImmunoPharmaceuticals Corp. and Shionogi BioResearch Corp. (both with Nobel laureate Dr. Susumu Tonegawa); Caxton Life Science Partners; Taiwan Global BioFund; TaiMed Biologics; Mevion Medical Systems; Cancer BioScience; Cancer Genetics; Kava Pharmaceuticals; SinglePixel BioMedical; Quercegen Pharma; Synta Pharmaceuticals and Sequential Medicine.
Dr. Chen currently serves as the Chairman of CHO Pharma, a Taiwan-based biopharmaceutical company focused on the development and commercialization of proprietary glycan engineering technologies .
Dr. Chen has served as a Senior Consultant for numerous large pharmaceutical firms, and has led the development or consulted for more than a dozen drugs and drug candidates.Dr. Chen was elected as an academician of the Academia Sinica of Taiwan in 1996. He received his B.S. in chemistry from National Taiwan University and Ph.D. in cell biology from the Massachusetts Institute of Technology.
Ms. Delagardelle is a Managing Director and leads New Leaf Venture’s medical device practice, with almost 30 years of experience in that industry. She joined Sprout in August 2000 and became General Partner in July 2001. She was one of the founders of New Leaf Venture upon its spin-out from Sprout in 2005.
Previously, she was a General Partner at Weiss, Peck & Greer Venture Partners where she focused on healthcare/technology investments. Before joining Weiss, Peck & Greer Venture Partners, Ms. Delagardelle spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry. Specifically, she was Vice President of Global Marketing for Target Therapeutics and spent nine years with the Medi-tech division of Boston Scientific in several senior management roles. In addition, Ms. Delagardelle served as Director of Business Operations for Roche Laboratories and Director of Global Marketing for Cell Pro, Inc. Ms. Delagardelle attended University of California at Irvine (M.B.A.) and Occidental College (A.B.).
Mr. Salahieh is a seasoned medical device entrepreneur with over 20 years of experience in the medical device industry. He is the founder of Shifamed, from which Apama Medical, Maya Medical and Kalila Medical were formed. Maya Medical was sold to Covidien in 2012 for $230 million and Kalila Medical was sold to Abbott in 2016. Prior to Shifamed, he co-founded Sadra Medical, a percutaneous aortic valve replacement company, raising $33 million in financing and leading the company to its first in-human milestone. Sadra Medical was sold to Boston Scientific for $450 million in January of 2011. Previously, as VP of R&D at Boston Scientific, Mr. Salahieh brought the FilterWire EX to the US market. He also played an active role in building EPI and in its acquisition by Boston Scientific. He has extensive R&D management experience stemming from his engineering consulting firm, Sobek Medical LLC which he sold to EPI, and from his work at CardioThoracic Systems and Guidant. He has also served as board member and advisor to a number of medical device companies including Atheromed Inc., SquareOne Inc., and TriReme Medical, Inc.
Mr. Salahieh is either the inventor or co-inventor on 104 granted and 137 published US patent applications. He holds a B.S. in Biomedical Engineering and a B.S. in Electrical Engineering from Case Western Reserve University.
Mr. Aguilera has been involved in the securities industry for over 26 years as an advisor to high net worth individual investors.
Mr. Aguilera is the Founder of BioRevolution Capital Management, LLC. He acted as an advisor from 2007 to 2013 to Global Advisory Services Group, LLC (based in New York City) in the biotech field, and specializes in developing potential strategic partnerships with international pharmaceutical companies. Mr. Aguilera was a Senior Financial Consultant at Great Eastern Securities, Inc. and Sandgrain Securities, Inc. from June 2002 to January 2007. From April of 1999 until joining Sandgrain, Mr. Aguilera was a Senior Vice President at Josephthal & Co., Inc., which was subsequently acquired by Fahnestock & Co., Inc. Mr. Aguilera was at DH Blair & Co. Inc. from 1984 until DH Blair & Co. was acquired by Barington Capital Group, L.P., and remained at Barington Capital Group, L.P. until April of 1999. In each of these positions Mr. Aguilera’s experience was in the biotechnology sector. Through this experience he has developed a specialization in biotechnology companies (biotechnology companies having a market capitalization of up to half a billion dollars). This experience led to a twelve month financial consulting position with Vion Pharmaceuticals, a cancer research company, beginning in December of 1998.
Mr. Aguilera is a graduate of Adelphi University, where he received a B.S. in Finance in May 1984.
Mr. Sellers is a pharmaceutical and biotechnology executive with over 37 years of management experience including extensive international success. Active as a consultant, he currently is the Chief Executive Officer and Chairman of CardioPharma, Inc., a cardiovascular company start-up, board member of Certus, Inc., an oncology company start-up, on the Business Advisory Board of WI Harper, a San Francisco and Asian based investment group, and a member of Life Science Angels, a San Francisco Bay Area angel investing group. From 1993 to 2004, Mr. Sellers served as President, Chief Executive Officer and a director of SciClone Pharmaceuticals, Inc., a public company. While at SciClone he also established a profitable international subsidiary and created the clinical and marketing programs that resulted in the highly successful marketing of China’s leading imported finished pharmaceutical product, Zadaxin®. Prior to SciClone, Mr. Sellers’ global pharmaceutical industry experience included work with Pfizer, the Revlon Healthcare Group, a regional Presidency with Sterling Drug International and the Pritzker organization, where he served as a Corporate Vice-President focused on pharmaceuticals and biomed devices and President of Muller & Phipps Japan. Mr. Sellers spent five years in military intelligence serving as an officer with Special Forces and as a counter-intelligence Special Agent.
Mr. Sellers received an A.B. degree from Lafayette College and a Master of International Management degree with honors from the Thunderbird Graduate School of International Management.
塞勒斯先生是一位制藥和生物技術領域的執行官，擁有超過37年的管理經驗，包括大量成功的國際經驗。作爲一名活躍的顧問，他目前是新成立的致力于心血管制藥的CardioPharma公司的首席執行官和董事長，同時也是Certus公司 – 一家新成立的腫瘤研究公司的董事會成員，並且是美國中經合集團（WI Harper） – 一家總部位于舊金山和亞洲的投資集團的商業咨詢委員會的顧問，以及Life Science Angels公司 – 一家位于舊金山港灣區的天使投資集團的成員。從1993年到2004年，塞勒斯先生擔任上市公司賽生制藥股份有限公司的總裁、首席執行官和總監。任職期間他成立了一家盈利的國際子公司並推出了醫療和市場項目，向中國成功推廣了後來成爲中國領先進口藥品的日達仙。在進入賽生之前，塞勒斯先生在全球制藥行業的工作經驗包括在輝瑞、露華濃醫療保健集團工作，在Sterling國際制藥公司和Pritzker組織擔任地區總裁職務，在後者他擔任專管制藥和生物醫學設備公司副總裁，並擔任了Muller & Phipps日本公司的總裁。塞勒斯先生在美國軍事情報部門擁有5年工作經曆，擔任特種部隊官員和反情報特工。